Asti Swari Paramanindita
Research Subjects
Asti Swari Paramanindita has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Budi Prasaja
P.T. Clinisindo Laboratories, Jakarta, Indonesia
1 shared publicationMonika Sandra
P.T. Clinisindo Laboratories, Jakarta, Indonesia
1 shared publicationRaden Efi Sofiah
P.T. Clinisindo Laboratories, Jakarta, Indonesia
1 shared publicationTri Rahayu Wijayanti
P.T. Clinisindo Laboratories, Jakarta, Indonesia
1 shared publicationWindy Lusthom
P.T. Clinisindo Laboratories, Jakarta, Indonesia
1 shared publicationYahdiana Harahap
Faculty of Pharmacy, University of Indonesia, Depok, Indonesia
1 shared publication
Latest Publications
- 2 October 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (11) , 1747-1752
A bioequivalence study of two telmisartan 80 mg tablets in healthy Indonesian subjects: an open label, three-way, three-period, partial replicate crossover study
Telmisartan is highly variable drug indicated for treatment of hypertension. This study aimed to compare the bioavailability of two 80 mg telmisartan tablets in healthy Indonesian subjects. A randomized, open-label, single-dose, three-sequence, three-way, reference-formulation-replicated crossover study was conducted under fasting period with two-week washout period. In this study, thirty-one Indonesian subjects were enrolled and twenty-eight subjects were completed the study. Serial blood samples were collected up to 72 hours following drug administration. Plasma concentrations of telmisartan were determined using high performance liquid chromatography method with fluorescence detector. The pharmacokinetic parameters of AUC0-t, AUC0-∞, and Cmax were assessed for bioequivalence. Bioequivalence acceptance was based on predefined criteria of 90% confidence interval of 80.00-125.00% for AUC parameters and reference-scaled-average bioequivalence of 71.73-139.42% for Cmax. The 90% confidence interval for AUC0-t, AUC0-∞, and Cmax were 96.11%-107.25%, 93.06%-104.36%, and 94.23%-127.01%, respectively. These results indicated that the two formulations of telmisartan were bioequivalent.
- 2 October 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (11) , 1747-1752
A bioequivalence study of two telmisartan 80 mg tablets in healthy Indonesian subjects: an open label, three-way, three-period, partial replicate crossover study
Telmisartan is highly variable drug indicated for treatment of hypertension. This study aimed to compare the bioavailability of two 80 mg telmisartan tablets in healthy Indonesian subjects. A randomized, open-label, single-dose, three-sequence, three-way, reference-formulation-replicated crossover study was conducted under fasting period with two-week washout period. In this study, thirty-one Indonesian subjects were enrolled and twenty-eight subjects were completed the study. Serial blood samples were collected up to 72 hours following drug administration. Plasma concentrations of telmisartan were determined using high performance liquid chromatography method with fluorescence detector. The pharmacokinetic parameters of AUC0-t, AUC0-∞, and Cmax were assessed for bioequivalence. Bioequivalence acceptance was based on predefined criteria of 90% confidence interval of 80.00-125.00% for AUC parameters and reference-scaled-average bioequivalence of 71.73-139.42% for Cmax. The 90% confidence interval for AUC0-t, AUC0-∞, and Cmax were 96.11%-107.25%, 93.06%-104.36%, and 94.23%-127.01%, respectively. These results indicated that the two formulations of telmisartan were bioequivalent.